bioXXmed AGXETRA bioXXmed Stock Report

bioXXmed AG is a biotechnology company, which engages in the research and development of therapies to treat cause of diseases. The company is headquartered in Darmstadt, Hessen and currently employs 0 full-time employees. The company went IPO on 2007-05-18. The firm holds interests in research and development (R&D) companies DermaTools Biotech GmbH, which is active in the field of dermatology and urology, and CytoPharma GmbH, which is engaged in product development for cardiovascular diseases, cancer and other indications. bioXXmed AG manages the patent portfolio and coordinates the licensing for its subsidiaries. The product pipeline of disease modifying therapies based on the mechanisms of cell growth and programmed cell death, comprising small molecules and biologics across a range of disease indications, includes DermaPro, the Company's lead product indicated for diabetic and venous foot ulcers in phase III of clinical trials, as well as Utisept, an urological medical device for flushing the bladder in urinary tract infections.